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ABSTRACT
Background: Lactase is an enzyme that hydrolyzes lactose into
glucose and galactose in the small intestine, where they are absorbed.
Hypolactasia is a common condition, primarily caused by genetic
programming, that leads to lactose maldigestion and, in certain cases,
lactose intolerance. Galactitol and galactonate are 2 products of
hepatic galactose metabolism that are candidate markers for the
intake of lactose-containing foods.
Objectives: The primary objective of the study was to explore the
changes in serum and urine metabolomes during postprandial dairy
product tests through the association between lactase persistence
genotype and the postprandial dynamics of lactose-derived metabo-
lites.
Methods:We characterized the 6-h postprandial serum kinetics and
urinary excretion of lactose, galactose, galactitol, and galactonate
in 14 healthy men who had consumed a single dose of acidified
milk (800 g) which contained 38.8 g lactose. Genotyping of LCT-
13910 C/T (rs4988235) was performed to assess primary lactase
persistence.
Results: There were 2 distinct postprandial responses, classified as
high and low metabolite responses, observed for galactose, and its
metabolites galactitol and galactonate, in serum and urine. In all
but 1 subject, there was a concordance between the high metabolite
responses and genetic lactase persistence and between the low
metabolite responses and genetic lactase nonpersistence (accuracy
0.92), galactitol and galactonate being more discriminative than
galactose.
Conclusions: Postprandial galactitol and galactonate after lactose
overload appear to be good proxies for genetically determined lactase
activity. The development of a noninvasive lactose digestion test
based on the measurement of these metabolites in urine could be
clinically useful. This trial was registered at clinicaltrials.gov as
NCT02230345. Am J Clin Nutr 2019;109:470–477.
Keywords: galactose metabolism, lactase activity, lactose, milk
digestion, nutrigenetics; personalized nutrition
Introduction
Lactose is a disaccharide composed of glucose and galactose
and is found mainly in milk and dairy products, but also
in many manufactured food products (1). The digestion of
lactose requires the presence of lactase, which hydrolyses the
sugar in the small intestine brush border, after which the 2
monosaccharides are absorbed via passive diffusion or active
transport. In most humans, a reduction in lactase activity (LA)
occurs in late childhood through epigenetic programming (2).
Consequently, undigested lactose reaches the colonic micro-
biota, resulting in the production of short-chain fatty acids,
hydrogen, and methane (3). For between one-third and one-
half of individuals with such lactose maldigestion (LM), these
fermentation products can cause gastrointestinal symptoms such
as diarrhea, abdominal pain, bloating, flatulence, and vomiting
after the ingestion of milk products, thus defining the clinical
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manifestations of lactose intolerance (LI). On the other hand,
∼35% of the world’s population retain intestinal LA similar to
infantile levels throughout adulthood (4). This lactase-persistence
phenotype is owing to polymorphisms in the promoter of the
lactase gene (LCT) that eliminate the programmed reduction in
activity of the promoter with age. Several prevalent mutations
of the LCT promoter have been described in populations or
ethnic groups that have a long history of herding animals,
suggesting an evolutionary advantage of this phenotype in these
groups.
Different methods are currently used to diagnose LM (5).
Jejunal biopsy, by allowing the direct measurement of LA, is
considered the gold standard method, but it is invasive, with
patchy results. Conversely, genetic testing of primary lactase
persistence is noninvasive but can lead to false results in the case
of genetic heterogeneity (6) or where secondary causes of LM
are present. The lactose tolerance test (LTT) and the recently
developed gaxilose test (7) both allow indirect evaluation of LA
through absorption testing, whereas the lactose hydrogen breath
test (LHBT) is based on testing the colonic consequences of
LM. These methods are widely used but can be unreliable and
difficult to interpret in clinical practice (8–10). The development
of a complementary method that would address some of the
major limitations of the available tests could be clinically
useful.
We have recently shown that both lactose and galactose are
present in blood after the ingestion of milk and yogurt (11). Once
absorbed, the majority of galactose enters the Leloir pathway,
where it is metabolized to UDP-glucose. However, it can also
enter 2 other hepatic pathways, to be either reduced to galactitol
by aldehyde reductase or oxidized to galactonate by galactose
dehydrogenase (12). Both galactitol and galactonate have been
identified as candidate biomarkers of lactose-containing food
intake in serum (13) and urine (14). We therefore hypothesized
that these 2 metabolites might also be good proxies of
LA .
Methods
Samples were obtained from a recently published crossover
study that was designed to evaluate the metabolic impact of acute
and prolonged intake of yogurt and acidified milk in 14 healthy
men (11, 15–17). Supplemental Figure 1 provides a flowchart of
the participants. Details on the study design have been published
elsewhere (15).
Subjects
Subjects were healthy male volunteers (n= 14) who regularly
consumed milk, with a mean ± SEM age of 25 ± 1.3 y
(recruitment range of 18–40 y) and a mean ± SEM body
mass index of 22 ± 0.5 kg/m2 (recruitment range of 18.5–
25.0 kg/m2). Of the subjects, 13 were Caucasian and 1 was
black African. A detailed tabulated description of these subjects
has been published elsewhere (15). The overall study received
ethical approval from the Commission cantonale d’éthique de la
recherche sur l’être humain (CER-VD, approval number: 392/13,
Vaud, Switzerland); the trial was registered at clinicaltrials.gov as
NCT02230345.
Test products
Both milk and yogurt were tested in a crossover design but,
as the fermentation process led to large changes in lactose and
galactose concentrations in yogurt (11), only data related to milk
intake are presented in this report. The ingested milk was full fat,
homogenized, and ultrahigh-temperature processed (provided
by Emmi Mittelland Molkerei AG). The milk was acidified
by the addition of 2% D-(+)-glucono-δ-lactone (≥99.0%;
Jungbunzlauer AG) to mimic the texture of the test yogurt, as
described previously (15).
Dietary intervention
The postprandial tests were performed at the Center of Clinical
Research of CHUV in Lausanne. Briefly, each participant
ingested a single 800 g dose of acidified milk, containing 38.8
g lactose. The test product was ingested within 15 min in the
fasted state, and serum was taken postprandially at 10 time points
(fasting, then at 15, 30, 60, 90, 120, 180, 240, 300, and 360 min).
Urine was collected in the morning before the acidified milk
ingestion, as well as during the 6-h postprandial phase (pooled
sample). Samples were stored at −80◦C prior to analysis. During
the 3 wk preceding the test day, participants consumed 400 g of
normal milk per day and followed a supervised diet (15).
Genetic test for lactase persistence
Genotyping of rs4988235, the most common single nucleotide
polymorphism (SNP) associated with lactase persistence in
Northern European population (LCT-13910 C>T polymor-
phism), was performed with the EliGene® Lactose Intolerance
C-13910T LC Kit (Elisabeth® Pharmacon) according to man-
ufacturer’s instructions. Real-time polymerase chain reaction
was carried out using the Lightcycler 96 (Roche), with internal
standards for positive and negative controls. Homozygous
carriers of the wild-type allele (CC) were considered to be
lactase nonpersistent (n = 8), whereas heterozygous (CT) and
homozygous carriers for the mutated allele (TT) were lactase
persistent (n = 5). Subject F3_009, of African origin, was
excluded from the statistical analyses because genotypes at
rs4988235 were not relevant for diagnosis of lactase persistence
in this population.
Serum and urine lactose, galactose, galactitol, and
galactonate gas chromatography–mass spectrometry
analysis
The primary endpoint of the original overall study reported
by Pimentel et al. (16) was the untargeted metabolomic profile
of serum after ingestion of yogurt and milk products. Secondary
endpoints, including the blood cell transcriptome (17), as well
as metabolic, inflammatory, and gut microbiota parameters, have
been published separately (15). This report now investigates
the postprandial behavior in serum and urine of 4 metabolites
related to themetabolism of lactose (lactose, galactose, galactitol,
and galactonate) after ingestion of the milk product as a
function of the genetic profile for lactase persistence. Serum
and urine samples were analyzed using an untargeted gas
chromatography–mass spectrometry (GC–MS) metabolomics
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method. Supplemental Figure 2 provides examples of the
chromatograms and spectra of lactose, galactose, galactitol, and
galactonate. These molecules derive from lactose metabolism
(Supplemental Figure 3) andwere among themetabolites whose
relative concentration changed the most following dairy intake.
They were, therefore, evaluated for their capacity to indirectly
reflect LA. Samples were prepared according to the Human
Serum Metabolome Consortium (HUSERMET) procedure (18)
with small modifications, as previously described (11, 14). Prior
to analysis, each urine samplewas diluted according to its specific
gravity, as calculated from the refractive index by refractometry,
with the use of an RE40 refractometer (Mettler-Toledo). GC-MS
measurements were performed using an Agilent 7890B/5977A
GC-MS system, 70 kV, equipped with a 60m× 0.250mm× 0.25
μm DB-5MS column (Agilent Technologies) (11, 13, 14). The
selected metabolites were determined with level 1 identification
(19) by the injection of pure standard solutions (14) of lactose and
galactose fromMerck and galactitol and galactonate from Sigma-
Aldrich. The serum and urine samples were analyzed in batches,
each batch containing the samples from one subject. The samples
from each subject were randomized. The order of the analyses of
the subjects was also randomized. The analytical laboratory was
blinded to the sample identity.
Statistical analyses
All statistical analyses were performed using R (3.1.2), with
0.05 as the P value significance cutoff. Linear evaluation of the
incremental area under the curve [iAUC; MESS package V.0.3.2
(20)] over 6 h was completed for each of the 4 metabolites in
postprandial serum. The Wilcoxon’s signed-rank test was used
to compare the intensities of lactose, galactose, galactitol, and
galactonate between subjects with andwithout lactase persistence
genotypes, in serum (iAUC) and in urine (postprandial 6 h pool).
A nonparametric longitudinal analysis (nparLD) was performed
to confirm the presence of a time effect for the serum metabolites
by lactase persistence genotype [package nparLD V.2.1 (21)].
A partial Spearman’s correlation test, controlling for lactase
persistence [ppcor package V.1.1 (22)], was used to assess the
relationships between the metabolites in serum or urine and
between serum and urine intensities of the same metabolite.
Results
The postprandial serum kinetics of lactose in serum showed
an increase between 2 and 3 h after ingestion of milk and a
return to nearly baseline levels by 6 h for most subjects (Figure
1A). Although postprandial responses were more significant for
the CC carriers (n = 8) (nparLD, P = 1.56 × 10−17) than for
the CT and TT carriers (n = 2 and 3, respectively) (nparLD,
P = 2.49 × 10−6), there was no significant difference between
the 2 groups when comparing the iAUCs (P = 0.72, Figure 1E),
as previously described (11).
Conversely, the postprandial kinetics of galactose (Figure
1B) and its metabolites galactitol (Figure 1C) and galactonate
(Figure 1D) in serum showed 2 distinct patterns according to
the LCT genotypes. For the CT and TT carriers, galactose
increased significantly, although variably, from 30min to 3 h after
ingestion of acidified milk compared with fasting values, before
returning to fasting levels (nparLD P = 9.50 × 10−5), whereas
galactitol and galactonate both increased continuously from the
first hour and during the 6 h (nparLD, P = 4.36 × 10−15 and
nparLD, P = 7.76 × 10−22, respectively). For the CC carriers,
the intensities of galactose and galactitol remained unchanged
compared with fasting values (nparLD P > 0.05), whereas
galactonate showed a small but significant postprandial response
(nparLD P = 1.49 × 10−3). These postprandial responses
appeared to be consistent between the subjects of each genotype
group, with the exception of 1 subject (subject F3_015) who was
homozygotic for the wild-type allele (CC) and who displayed
postprandial responses similar to that of the CT and TT carriers.
In accordancewith these observations, the iAUCs for galactose
(Figure 1F), galactitol (Figure 1G), and galactonate (Figure 1H)
were significantly higher in CT and TT carriers than in CC
carriers (Wilcoxon’s signed-rank test, P = 0.023, P = 0.011,
and P = 0.0031, respectively). A cutoff value for each of the
3 metabolites could clearly separate the subjects from the 2
groups, with the exception of subject F3_015, as mentioned
above. Statistics on serum data comparing CT and TT carriers
and CC carriers at each time point are given in Supplemental
Table 1.
Interindividual variability in the postprandial responses of
lactose (Figure 1I), galactose (Figure 1J), galactitol (Figure
1K), and galactonate (Figure 1L) was also observed in urine.
In contrast to the observations in serum, CC carriers had
significantly higher postprandial urinary levels of lactose than
CT and TT carriers (P = 0.019) (see Figure 1I, Supplemental
Table 1), although there was no clear cutoff level to separate the
2 groups. Conversely, the galactose, galactitol, and galactonate
intensities in urinewere significantly higher in CT and TT carriers
than in CC carriers (Wilcoxon’s signed-rank test, P = 0.030,
P = 0.030, and P = 0.019, respectively). In addition, a cutoff
could clearly separate the subjects from the 2 groups, with
the exception of subject F3_015, who showed a discrepancy
between genotype and urine metabolite responses similar to the
response observed in serum. Significant positive correlations
between serum and urine intensities were observed for galactose,
galactitol, and galactonate (P = 3.10 × 10−4, P = 1.06 × 10−2,
and P = 6.70 × 10−3, respectively), with a clear bimodal
separation between lactase-persistent and -nonpersistent subjects
(Figure 2), the best separation being observed for galactonate
(see Figure 2D). In the comparisons made between galactose,
galactonate, and galactitol, subject F3_009 (African origin)
clearly clustered with the lactase-nonpersistent genotype group,
whereas subject F3_015 (CC genotype) clustered with the
lactase-persistent genotype group.
Combining pairs of metabolites either in serum (upper panels
of Figure 3) or in urine (lower panels of Figure 3) even
strengthened the capacity to separate the 2 profiles, although
galactose was the least discriminative of the 3 metabolites in both
fluids, and galactonate was the most discriminative in urine.
Of note, the CT and TT carriers (n = 2 and n = 3,
respectively) appeared to exhibit similar metabolite profiles for
the 4 metabolites both in serum and in urine, although this could
not be statistically confirmed owing to the small number of
samples (see panels E–L of Figure 1, and also Figures 2 and 3).
The accuracy of galactose, galactitol, and galactonate serum
or urine measurements after milk ingestion to predict lactase
persistence determined genetically was 0.92 in this study (12 out
of 13 subjects were concordant).
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FIGURE 1 Genetic dependency of the postprandial behavior of lactose-derived metabolites after intake of acidified milk. Serum lactose (A), galactose
(B), galactitol (C), and galactonate (D) after milk intake in 14 healthy subjects. Participants with CC (solid grey, n = 8) and CT or TT (solid black, n = 5)
or nondetermined (black dashed, n = 1) genotype at rs4988235. Comparison of postprandial serum (iAUC) lactose (E), galactose (F), galactitol (G), and
galactonate (H) after milk intake between CC (grey circles, n = 8), CT (black circles, n = 2), and TT (black triangles, n = 3) carriers in 13 healthy subjects.
Comparison of postprandial urine (6-h pool) lactose (I), galactose (J), galactitol (K), and galactonate (L) after milk intake between CC (grey circles, n= 8), CT
(black circles, n = 2), and TT (black triangles, n = 3) carriers in 13 healthy subjects. Boxplots indicate medians and interquartile ranges. The Box-Whiskers
plots indicate medians, interquartile ranges, and minimum and maximum values excluding outliers. ∗P < 0.05, Wilcoxon’s signed-rank test between CC and
CT or TT genotypes. Subject F3_009, who was of African origin, was excluded from the statistical analyses of panels E–L because genotypes at rs4988235
were not relevant for diagnosis of lactase persistence in this population. iAUC, incremental area under the curve.
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FIGURE 2 Correlation between postprandial serum and urine lactose (A), galactose (B), galactitol (C), and galactonate (D) after milk intake in 14 subjects.
Partial Spearman’s correlation test controlling for lactase persistence. Participants with CC (grey circles, n= 8), CT (black circles, n= 2), TT (black triangles,
n = 3), or nondetermined (unfilled circle, n = 1) genotype at rs4988235. Subject F3_015 is indicated on the figure. iAUC, incremental area under the curve.
Discussion
We have shown that galactose and 2 of its metabolites,
galactitol and galactonate, present a bimodal (high or low)
postprandial response after milk ingestion both in serum and
in urine. In 92% of our cases, these responses matched the
genotype at rs4988235 for lactase persistence. We therefore
propose that the measurement of these 3 metabolites after a
lactose overload could be a good proxy for LA. We could not
identify distinct metabolite profiles between heterozygous (CT)
and homozygous (TT) carriers of themutated T allele that confers
lactase persistence. This is in line with a previous report of similar
blood glucose response after lactose overload in both groups (23).
However, it is not excluded that by studying a larger number
of subjects it would be possible to identify an intermediate
phenotype for the LCTC/T heterozygotes, in accordance with the
gene dosage effect on jejunal LA that has been recently described
(24).
For 1 subject (F3_015), the observed phenotype did not corre-
spond with the phenotype expected for his lactase-nonpersistent
genotype; instead, a high LA was suggested by the metabolite
postprandial responses. However, we typed only the most
common polymorphism associated with lactase persistence in
Northern European populations, and the subjects we recruited
were of diverse origins. It is therefore likely that we missed
a relevant polymorphism in this subject owing to genetic
heterogeneity. Indeed, one of the major limitations in lactase
genetic testing is that, in genetically diverse populations (such as
in Europe), targeted analysis of SNPs may not comprehensively
evaluate lactase persistence (25). In this context, we excluded
subject F3_009, who was of African origin, from the analyses
because the SNP typed in this study was specific to Caucasians;
however, we observed that this volunteer presented a postprandial
metabolite response suggestive of a low LA, which is the most
common phenotype in this population (26). For both subjects, the
metabolic challenge would have been more specific or sensitive
than the available genetic test to detect lactase persistence or
nonpersistence.
Of the existing LM tests, several involve the administration
of a lactose load; in the LTT, 50 g of lactose is usually
administered, whereas for the LHBT, the recommended lactose
dose has recently been reduced to 25 g (27). In the present
challenge, an intake of 38.8 g lactose was sufficient to separate
2 metabolic profiles with clear cutoffs for galactose, galactitol,
and galactonate, both in serum and in urine. Galactose is rapidly
metabolized after absorption mainly via the Leloir pathway and
does not accumulate in the organism in normal conditions (see
Supplemental Figure 2) (28). The Leloir pathway is regulated
by the rate-limiting enzyme galactokinase, but 2 alternative
pathways can be activated that generate either galactitol or
galactonate from galactose, 2 metabolites that are not further
metabolized but are instead eliminated in urine. It is therefore
not surprising that these downstream metabolites were more
discriminant than galactose. Although the measurements in urine
were completed on 6-h pooled samples, a body of evidence
suggests that a measurement of galactitol and galactonate in a 3-h
urine pool should be sufficient to discriminate high and low LA:
1) the kinetics of the metabolites in serum indicate discrimination
of LA at 3 h (see panels C and D in Figure 1); 2) serum and urine
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FIGURE 3 Correlation between postprandial serum galactose and galactitol (A), galactose and galactonate (B), and galactonate and galactitol (C), and
between postprandial urine galactose and galactitol (D), galactose and galactonate (E), and galactonate and galactitol (F), after milk intake in 14 subjects. Partial
Spearman’s correlation test controlling for lactase persistence. Participants with CC (grey circles, n= 8), CT (black circles, n= 2), TT (black triangles, n= 3),
or nondetermined (unfilled circle, n = 1) genotype at rs4988235. Subject F3_015 is indicated on the figure. iAUC, incremental area under the curve.
measurements were highly correlated (see Figure 2); and 3) the
kinetics of galactitol in urine in the previous study of Münger et
al. (14) indicate that the excretion of galactitol peaks between 2
and 4 h after the ingestion of 600 ml of milk. The suitability of
3-h urine pools, however, needs to be confirmed in a larger study.
We propose that the measurement of galactitol and galactonate
in urine could be used as a new noninvasive test for the accurate
evaluation of LA and subsequent diagnosis of normal lactasia
or primary or secondary hypolactasia. The test showed high
sensitivity (87.5%) and high specificity (100%) in our study, in
which only genetic testing was used as the reference for LA. It is
likely that the sensitivity would have been higher if the LA had
been accurately assessed by other methods, such as LTT, LHBT,
or jejunal biopsy, for all the subjects in this study. The advantage
of this new test is that its performance would not be altered in
clinical conditions that limit or invalidate the interpretation of
other available LM diagnostic tests. For example, the precision
of the test is not reduced owing to the presence of impaired
glucose tolerance as for the LTT, the test is not overly influenced
by microbiota modifications like the LHBT, and the test is not
affected by genetic heterogeneity, which limits the use of the
SNP-based genetic testing. In addition, given that the ingestion of
lactose is required for the test, the evaluation of gastrointestinal
symptoms could be used to concomitantly diagnose LI. This
would be an advantage compared with the gaxilose test, which
uses a synthetic analog of lactose not found in food matrices as a
substrate for lactase and which does not allow the assessment of
LI symptoms.
There are nevertheless some potential limitations to our
proposed test. First, urinary concentrations of galactitol and
galactonate will be influenced by subjects’ renal excretion rates
and urine dilution. Adjusting the concentrations based on urine
creatinine content or specific gravity, as done in the present study,
might therefore be necessary to reduce interindividual variability.
Second, the validity of the test relies on the correct functionality
of enzymes that act in 2 distinct metabolic processes, namely,
gastrointestinal hydrolysis of lactose and hepatic metabolism
of galactose. As such, the test is likely to be affected by
any gastrointestinal, hepatic, or renal dysfunctions. Indeed, the
course of galactose elimination capacity is used to monitor
survival in patients with cirrhosis (29). Conversely, in patients
with galactosemia, who present a defect in enzymes of the
Leloir pathway, alternative pathways are activated, resulting in
accumulation of galactitol and galactonate (30). In such cases, the
test would not be sensitive to LM, and hence would not detect it.
Third, although a test based on metabolites has an advantage over
the genetic test in being phenotypic, and hence clinically more
relevant, GC-MS-based tests are costly, and such technologies are
not available in many centers. However, enzymatic tests based on
bacterial enzymes specifically hydrolyzing galactosemetabolites,
in particular galactonate (31), may be validated as alternatives to
the GC-MS-based test.
The identification of 2 different galactose metabolite excretion
profiles that depend on LA raises the question of whether these
metabolites are appropriate food intake biomarkers of lactose-
containing foods in subjects with lactase nonpersistence (13,
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14). In a pilot study, we were able to identify galactitol and
galactonate in urine after the ingestion of only 10 g of lactose,
with a dose response (ingestion of 20 and 40 g of lactose)
in subjects with lactase persistence but not in subjects with
lactase nonpersistence (G Vergères, unpublished data). This
suggests that absorption of dietary portions of lactose can activate
pathways of galactose metabolism that are alternatives to the
Leloir pathway in all subjects regardless of their lactase status,
but that the measurement of these metabolites in urine would
be only qualitative and not quantitative in subjects with lactase
nonpersistence. Thus, our proposed test would likely not be
discriminative of LA if the dose of lactose was much lower than
40 g.
In conclusion, hypolactasia is a highly prevalent disorder
that is often difficult to diagnose. An accurate assessment of
LA in subjects experiencing gastrointestinal discomfort could
help to avoid inappropriate food restriction. The evaluation of
galactitol and galactonate in urine could be used as a noninvasive
test to determine LA. Additional, larger studies are needed
to confirm these results in different populations, including
populations with different genotypes, age groups (children,
adults, elderly), and genders. These studies should also confirm
the accuracy of the test in 3-h pooled urine and help to refine the
discriminative cutoff. Once validated, this indirect assessment of
LA could be highly relevant for clinical assessment of lactose
metabolism.
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